123663-75-2

Basic information

• Product Name: 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-2-chromonecarboxylic acid
• Synonyms: 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-2-chromonecarboxylic acid
• CAS NO: 123663-75-2
• Molecular Weight: 375.359
• Mol File: 123663-75-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-2-chromonecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-2-chromonecarboxylic acid(123663-75-2)
• EPA Substance Registry System: 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-2-chromonecarboxylic acid(123663-75-2)

Safety Data

• Hazardous Substances Data: 123663-75-2(Hazardous Substances Data)

Upstream product

• 108-95-2 phenol 
• 123664-52-8 methyl 2-hydroxy-4-methylsulfonylamino-5-phenoxyphenyl ketone 
• 123664-84-6 N-(5-methoxy-2-phenoxyphenyl)methanesulfonamide 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 76838-72-7 5-methoxy-2-phenoxyaniline 
• 84594-95-6 5-methoxy-1-nitro-2-phenoxybenzene 
• 123663-74-1 2-ethoxycarbonyl-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one 

Downstream Products

• 123664-65-3 7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one-2-carboxylic acid chloride 
• 123664-66-4 7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one-2-carboxylic acid azide 

Relevant articles and documents

Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models

A group of derivatives of 7-methanesulfonylamino-6-phenoxychromone (1) at the pyrone and phenoxy rings was synthesized starting with 4-chloro-3- nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals. Significant potency in the rat models of carrageenin-induced edema (CPE) and adjuvant-induced arthritis (AA) was realized with 2'-fluoro and 2',4'-difluoro derivatives (9a and 9d), and 3- formylamino derivative (19a) and its 2'-fluoro and 2',4'-difluoro compounds (22a and 22d), displaying AA therapeutic effect of ED40=2.5-7.1 mg/kg/d for 7 d and AA prophylactic effect of 53-70% inhibition at the dosage of 3 mg/kg/d for 22 d. To identify a candidate for further pharmacological study, the five compounds were subjected to evaluation of their gastro-ulcerogenic liability, leading to selection of the fluorine-free compound 19a which did not cause acute ulceration at 300 mg/kg in oral administration in rats. Compound 19a (ED40=3.6 mg/kg in established AA) possessed good therapeutic efficacy against type II collagen-induced arthritis in DBA/1J mice with doses of 30 and 100 mg/kg, suggesting the development of 19a (designated T-614) as a prospective disease-modifying antirheumatic agent. In addition, a preparative-scale synthetic route to T-614 has been established.